This report was first published by Endpoints News. To see the original version, click here
Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year.
Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut.
您已阅读21%（576字），剩余79%（2227字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。